Ipsen Delivers Strong Double-digit Sales Growth for the Third Quarter of 2019 and Confirms Full Year 2019 Guidance – BioSpace

Oct. 24, 2019 05:00 UTC

PARIS--(BUSINESS WIRE)-- Regulatory News:

Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical group, today announced sales for the third quarter of 2019.

Financial highlights

Recent pipeline highlights

Key figures

Unaudited IFRS consolidated sales

Third Quarter

Nine Months

(in million euros)

2019

2018

%

Variation

%

Variation

at constant

currency and

consolidation

scope1

2019

2018

%

Variation

%

Variation at

constant currency

and consolidation

scope 1

Specialty Care

574.2

484.1

18.6%

16.5%

1,674.1

1,404.2

19.2%

16.8%

Consumer Healthcare2

70.6

71.9

-1.8%

0.1%

200.2

216.2

-7.4%

-2.4%

Group sales

644.7

555.9

16.0%

14.5%

1,874.3

1,620.4

15.7%

14.3%

1 Subsidiaries involved in the partnership between Ipsen and Schwabe Group are consolidated in accordance with the equity method starting 1 January, 2019. Year-on-year growth excluding foreign exchange impact established by recalculating net sales for the relevant period at the rate used for the previous period.

David Meek, Chief Executive Officer of Ipsen stated: In the third quarter, we continued to execute on our objectives with a strong performance of our Specialty Care business, including double-digit growth of Somatuline in both the U.S. and Europe. With our excellent performance year-to-date, we are increasingly confident in our ability to achieve our 2019 financial guidance.

We remain focused on the successful execution of the palovarotene program to bring the first therapeutic treatment to FOP patients as expeditiously as possible. We also continue to deliver on our external innovation strategy. The recent in-licensing of BLU-782 reinforces our leadership in FOP with a different and potentially complementary mechanism of action to palovarotene, expands our portfolio approach in this complex ultra-rare bone disorder and leverages our clinical and commercial capabilities. Advancing our pipeline remains a key focus going forward to deliver on our growth strategy and to bring additional value to patients and shareholders.

Third quarter 2019 sales highlights

Note: Unless stated otherwise, all variations in sales are stated excluding foreign exchange impacts (currency effects established by recalculating net sales for the relevant period at the exchange rates from the previous period)

(in million euros)

2019

2018

% Variation

%

Variation

at constant

currency and

consolidation

scope21

Specialty Care

574.2

484.1

18.6%

16.5%

Somatuline

264.0

217.0

21.7%

18.8%

Decapeptyl

98.9

89.2

10.9%

Link:
Ipsen Delivers Strong Double-digit Sales Growth for the Third Quarter of 2019 and Confirms Full Year 2019 Guidance - BioSpace